重症肌无力(myasthenia gravis,MG)是临床常见的获得性自身免疫性疾病,病变主要累及神经-肌肉接头突触后膜上乙酰胆碱受体(acetylcholine receptor,AChR)。一般认为,AChR抗体参与了MG的发生,通过与神经肌接头处的AChR结合引发自身免疫反应,造成AChR数量的减少而产生肌肉收缩无力等临床症状[1-2]。因此AChR抗体在MG临床 Myasthenia gravis (MG) is a common autoimmune autoimmune disease in clinic. The pathological changes mainly involve the acetylcholine receptor (AChR) on the postsynaptic membrane of neuromuscular junction. It is generally believed that the AChR antibody is involved in the development of MG and induces an autoimmune reaction by binding to AChR at the neuromuscular junction, resulting in a decrease in the number of AChR resulting in clinical symptoms such as muscle weakness [1-2]. Therefore AChR antibodies are clinically in the MG